Summit Therapeutics launches Phase III ivonescimab trial in Stage III lung cancer
SMMT•Summit Therapeutics launched HARMONi-10, a global Phase III trial comparing ivonescimab with durvalumab in patients with unresectable Stage III lung cancer. Site activations are expected to begin in the fourth quarter of 2026.
1. Trial details
HARMONi-10 will study patients with non-small cell lung cancer whose disease has not progressed after platinum-based concurrent chemoradiation. The trial will assess whether ivonescimab delays disease progression compared with the current standard of care; it is the sixth company-sponsored Phase III ivonescimab study.




